Oryzon Financial Statements From 2010 to 2025
| ORYZF Stock | USD 3.36 0.33 10.89% |
Check Oryzon Genomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oryzon Genomics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Oryzon financial statements analysis is a perfect complement when working with Oryzon Genomics Valuation or Volatility modules.
Oryzon |
Oryzon Genomics SA Company Return On Equity Analysis
Oryzon Genomics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Oryzon Genomics Return On Equity | -0.0685 |
Most of Oryzon Genomics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oryzon Genomics SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Oryzon Genomics SA has a Return On Equity of -0.0685. This is 99.71% lower than that of the Healthcare sector and 99.81% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 77.9% lower than that of the firm.
Oryzon Genomics SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Oryzon Genomics's current stock value. Our valuation model uses many indicators to compare Oryzon Genomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Oryzon Genomics competition to find correlations between indicators driving Oryzon Genomics's intrinsic value. More Info.Oryzon Genomics SA is regarded fifth in return on equity category among its peers. It also is regarded fifth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Oryzon Genomics' earnings, one of the primary drivers of an investment's value.About Oryzon Genomics Financial Statements
Oryzon Genomics stakeholders use historical fundamental indicators, such as Oryzon Genomics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Oryzon Genomics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Oryzon Genomics' assets and liabilities are reflected in the revenues and expenses on Oryzon Genomics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Oryzon Genomics SA. Please read more on our technical analysis and fundamental analysis pages.
Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. The company was founded in 2000 and is based in Cornell de Llobregat, Spain. Oryzon Genomics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 43 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Oryzon Pink Sheet
Oryzon Genomics financial ratios help investors to determine whether Oryzon Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oryzon with respect to the benefits of owning Oryzon Genomics security.